| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGF1R |
| Uniprot No | P08069 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-932aa |
| 氨基酸序列 | EICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTV ITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGL YNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNEC CHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRD FCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPK VCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGL IEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQ LWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEA PFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVY VKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVK WNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDI EEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSI FVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEG ADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECV SRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGY EN |
| 预测分子量 | 104kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGF1R重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Recombinant human insulin-like growth factor receptor 1 (IGF1R) production and functional analysis for cancer research*
**作者**：Baserga, R., et al.
**摘要**：该研究描述了通过哺乳动物表达系统高效生产重组人IGF1R胞外域蛋白的方法，验证了其与配体(IGF-1/IGF-2)的结合活性，并证明其在肿瘤细胞增殖信号通路研究中的应用潜力。
2. **文献名称**：*Structural insights into IGF1R activation by recombinant protein engineering*
**作者**：Christopoulos, A., et al.
**摘要**：利用重组IGF1R蛋白的晶体结构解析，揭示了受体与配体结合的分子机制，阐明了其二聚化及酪氨酸激酶活性的调控方式，为靶向药物设计提供了结构基础。
3. **文献名称**：*IGF1R signaling in metabolic diseases: Insights from recombinant protein-based assays*
**作者**：LeRoith, D., Roberts, C.T.
**摘要**：通过重组IGF1R蛋白建立的体外功能实验模型，分析了其在胰岛素抵抗和代谢综合征中的作用，探讨了靶向该受体改善糖脂代谢异常的可能性。
---
(注：以上文献名称与作者为虚拟示例，实际文献需通过PubMed或专业数据库检索。如需具体文章，建议查阅如*Journal of Biological Chemistry*、*Nature Structural & Molecular Biology*等期刊。)
Insulin-like growth factor 1 receptor (IGF1R) is a transmembrane tyrosine kinase receptor critical for regulating cellular growth, differentiation, and survival. It belongs to the insulin receptor family and shares structural homology with the insulin receptor. IGF1R is activated by its primary ligands, IGF-1 and IGF-2. as well as insulin at supraphysiological concentrations. Upon ligand binding, IGF1R undergoes autophosphorylation, initiating downstream signaling cascades such as the PI3K-AKT and MAPK pathways, which influence metabolic processes, cell cycle progression, and apoptosis evasion.
Discovered in the 1980s, IGF1R gained attention for its role in development and cancer biology. Knockout studies in mice revealed embryonic lethality due to growth retardation, underscoring its importance in prenatal development. In humans, dysregulated IGF1R signaling is implicated in various pathologies, including cancer (e.g., breast, prostate, and colorectal), metabolic disorders, and aging-related conditions. Tumor cells often overexpress IGF1R to enhance proliferation, survival, and metastasis, making it a therapeutic target.
Recombinant IGF1R proteins are engineered using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications, including glycosylation and disulfide bond formation. These proteins are purified via affinity chromatography and validated for functionality through ligand-binding assays and kinase activity tests. Researchers use recombinant IGF1R to study signaling mechanisms, screen inhibitory drugs (e.g., monoclonal antibodies or tyrosine kinase inhibitors), and develop diagnostic tools. Its application extends to understanding resistance mechanisms in targeted therapies and exploring cross-talk with other oncogenic pathways. Despite therapeutic challenges, such as compensatory signaling, IGF1R remains a focal point in precision medicine and cancer research.
×
